A peptide can bind to a receptor without strongly activating it.
Another peptide may require only a tiny concentration to produce a measurable response.
A third may activate several receptors, but with very different potency at each one.
This is why describing a molecule simply as an “agonist” leaves out much of the useful pharmacology.
Researchers use measurements such as EC50, binding affinity, potency, and efficacy to understand how a compound interacts with a receptor system.
Retatrutide provides a particularly useful case study because the molecule activates three related receptors rather than one.
It is active at:
- the GIP receptor
- the GLP-1 receptor
- the glucagon receptor.
But its activity is not identical across all three.
Understanding those differences helps explain both retatrutide and the broader science of multi-receptor peptide design. Buy Reta here.
What Is a Receptor Agonist?
A receptor is a biological molecule, usually a protein, that recognizes certain chemical signals.
When the appropriate ligand binds, the receptor can change conformation and initiate intracellular signaling.
An agonist is a ligand capable of activating that receptor.
Many peptide hormones function as natural agonists.
Examples include:
- GIP at the GIP receptor
- GLP-1 at the GLP-1 receptor
- glucagon at the glucagon receptor.
Synthetic peptide agonists can be engineered to mimic, modify, or combine these signaling properties.
Retatrutide is an unusual example because one synthetic peptide has agonist activity at all three receptor systems. The original discovery study described it as a triple GCGR, GIPR, and GLP-1R agonist.
What Does EC50 Mean?
One of the most common values in receptor pharmacology is EC50.
EC50 means the half-maximal effective concentration.
In a typical functional assay, researchers expose cells to increasing concentrations of a compound and measure a biological response.
This might be:
- cAMP production
- calcium signaling
- reporter-gene activation
- enzyme activity
- another downstream response.
The result often forms a concentration-response curve.
At very low concentrations, little response may occur.
As concentration increases, response increases.
Eventually, the system approaches its maximum measured response.
The EC50 is the concentration associated with 50% of that maximum response.
Lower EC50 Usually Means Greater Potency
When two compounds are tested under the same conditions at the same receptor, a lower EC50 generally indicates greater functional potency.
Imagine:
Compound A: EC50 = 0.1 nM
Compound B: EC50 = 10 nM
Compound A reaches half of its maximum measured effect at a concentration 100 times lower than Compound B.
Under those assay conditions, Compound A is therefore considered more potent.
But this comparison only works properly when the experimental systems are comparable.
Differences in:
- receptor density
- cell type
- signaling pathway
- assay duration
- laboratory protocol
can shift observed EC50 values.
An EC50 should therefore be interpreted as an assay-dependent functional measurement, not a universal physical constant.
Retatrutide Has Different Potency at Its Three Receptors
Functional assays using human receptors reported approximate EC50 values for retatrutide of:
| Receptor | EC50 |
|---|---|
| GIPR | 0.0643 nM |
| GLP-1R | 0.775 nM |
| GCGR | 5.79 nM |
These data show that the molecule is substantially more potent at human GIPR in the reported assay than at GLP-1R or GCGR.
This does not mean that 90% of retatrutide’s effects come from the GIP receptor.
Potency in an isolated receptor assay and physiological contribution in an intact organism are different questions.
Potency Is Not the Same as Efficacy
These terms are often confused.
Potency asks how much compound is needed to produce a given effect.
Efficacy asks how large an effect the compound can produce once the system is sufficiently activated.
Two compounds can therefore have:
- different potency
- but similar maximum efficacy.
Or:
- similar potency
- but different maximum efficacy.
A compound that reaches the same maximum receptor response as the reference full agonist can be described as having full agonist efficacy in that assay.
The retatrutide discovery work found functional agonist activity at all three intended receptor systems and described the molecule as showing balanced glucagon and GLP-1 receptor activity with stronger GIP receptor activity.
What Is a Full Agonist?
A full agonist is capable of producing the maximal response available in the particular receptor assay relative to the reference system.
A partial agonist activates the receptor but produces a lower maximal response even when receptor occupancy is high.
This distinction matters.
A partial agonist can sometimes have high binding affinity yet still fail to generate the same maximum downstream signaling response as a full agonist.
So binding strongly to a receptor is not enough to describe functional pharmacology.
Researchers need to know what happens after binding.
Binding Affinity and EC50 Are Not the Same Thing
Another common mistake is treating binding affinity as though it were identical to functional potency.
They answer different questions.
A binding experiment asks:
How strongly does this molecule associate with the receptor?
A functional assay asks:
What concentration produces a particular downstream response?
Binding affinity may be expressed using values such as:
- Kd
- Ki.
Functional potency may be described with:
- EC50.
These values can correlate, but they do not have to match.
A ligand may bind well but produce weak downstream signaling.
Receptor reserve can also allow a compound to produce substantial functional responses without occupying every available receptor.
What Is Ki?
Ki is an estimate of the inhibition or binding constant derived from competition-binding experiments.
Lower Ki values generally indicate stronger binding affinity under the conditions of the experiment.
Reported retatrutide binding data again show different affinities across its target receptors.
But it would be a mistake to look at Ki alone and declare one receptor the most important physiological target.
Receptor pharmacology is determined by the complete combination of:
- affinity
- functional potency
- efficacy
- receptor density
- tissue distribution
- signaling pathways
- drug exposure.
Why Multi-Receptor Peptides Are More Complicated
For a single-receptor peptide, researchers may be able to focus primarily on one concentration-response relationship.
A triple agonist creates at least three.
Each receptor can have a different:
- EC50
- binding affinity
- efficacy
- expression pattern
- downstream signaling response.
And the peptide concentration present in tissue changes over time.
This means the receptor contribution could theoretically change according to exposure.
At a relatively low free concentration, the highest-potency receptor might be strongly activated while the lower-potency receptor receives less stimulation.
At higher exposure, activity at the other receptors may increase.
That makes pharmacokinetics and pharmacodynamics inseparable when interpreting multi-receptor compounds.
Retatrutide Was Designed With an Uneven Receptor Profile
The original retatrutide study did not describe the molecule as having three perfectly equal receptor potencies.
Instead, the researchers reported more GIP receptor activity, with glucagon and GLP-1 receptor activity in a more similar range.
Relative to natural human ligands, later reviews summarize retatrutide as having approximately:
- 8.9-fold greater GIPR potency than native GIP
- 2.5-fold lower GLP-1R potency than native GLP-1
- 2.9-fold lower GCGR potency than native glucagon.
This is a good example of rational peptide engineering.
The goal is not necessarily to copy each natural hormone exactly.
It is to build a new pharmacological profile.
Why Not Maximize Every Receptor?
It might seem logical that the strongest possible agonism at all three receptors would produce the strongest biological response.
That is not necessarily true.
Different receptors can produce both desirable and undesirable physiological effects.
For example, glucagon receptor activation can increase energy expenditure and influence hepatic lipid metabolism, but glucagon signaling also promotes hepatic glucose production.
The scientific challenge is therefore not merely:
Can a peptide activate three receptors?
It is:
What balance of activity produces the desired overall biology?
Reviews of next-generation dual and triple agonists increasingly emphasize receptor balance as an important element of multi-agonist development.
Species Differences Matter Too
Another important issue is that receptor potency can differ between species.
A peptide may interact differently with mouse receptors than with human receptors.
That creates challenges when translating preclinical experiments.
For retatrutide, reported EC50 values for mouse receptors differ from the human values.
This means an exposure that produces one balance of GIPR, GLP-1R, and GCGR activation in mice may not produce exactly the same receptor balance in humans.
That is one of many reasons animal pharmacology cannot simply be converted directly into predicted human effects.
Cell Assays Are Simplified Biological Systems
Receptor assays are extremely useful because they let researchers isolate particular mechanisms.
But a cultured cell expressing one engineered receptor is not an entire organism.
In a human or animal:
- receptors occur in different tissues
- receptor expression varies
- hormones interact
- neural signaling contributes
- compounds distribute unevenly
- metabolism changes concentrations
- feedback systems modify responses.
So EC50 data tell researchers something highly specific and valuable.
They do not tell the entire biological story.
Why Researchers Need Well-Characterized Material for Receptor Assays
Receptor pharmacology is particularly sensitive to material quality.
Suppose a laboratory believes it is testing 10 nM of a peptide.
If the actual material has uncertain identity, concentration, or peptide content, the calculated concentration-response relationship may be inaccurate.
Impurities can introduce additional problems.
A peptide-related impurity might:
- lack biological activity
- retain some receptor activity
- have altered receptor selectivity
- interfere with analytical measurements.
For this reason, researchers conducting receptor or analytical work should pay attention to peptide identity and chromatographic characterization.
A lot-specific retatrutide research material intended for laboratory work should be evaluated based on the analytical documentation accompanying the specific lot, rather than relying only on the compound name.
EC50 Does Not Tell You an Appropriate Human Dose
This point is essential.
An EC50 of 0.775 nM at an engineered cell receptor does not translate directly into an amount that should be administered to a person.
Cell-based potency measurements do not account for:
- absorption
- distribution
- metabolism
- clearance
- protein binding
- tissue concentration
- safety
- off-target effects.
Clinical dose selection requires an entirely different body of pharmacokinetic, toxicological, and clinical evidence.
Retatrutide remains investigational. Lilly states that it has not been approved by any regulatory agency and remains under clinical study.
Receptor-potency values should therefore remain receptor-pharmacology data, not dosing instructions.
What Multi-Receptor Agonism Teaches Us About Modern Peptide Design
Retatrutide is part of a broader move away from simple one-target pharmacology.
The development pathway has progressed from:
single GLP-1 receptor agonism
to
dual GIP/GLP-1 receptor agonism
and now
GIP/GLP-1/glucagon triple agonism.
A 2025 review of next-generation receptor agonists describes several dual and triple strategies under investigation, reflecting increasing interest in coordinating several related metabolic pathways within one molecule.
This raises new design questions.
How much activity should each receptor receive?
Should the molecule be biased toward one receptor?
Do different tissues need different concentrations?
Does adding another receptor improve the desired outcome enough to justify additional biological complexity?
These are pharmacology questions that cannot be answered by looking at a peptide sequence alone.
Concentration-Response Curves Are More Informative Than One Number
Researchers often reduce an experiment to an EC50 value for convenience.
But the entire concentration-response curve contains more information.
Its characteristics can include:
- minimum response
- maximum response
- slope
- EC50
- variability
- evidence of partial agonism
- possible non-linear behavior.
Two agonists with similar EC50 values might have very different maximum responses.
Two compounds with the same maximum response could differ dramatically in potency.
For multi-receptor peptides, comparing full curves across each receptor can therefore be much more informative than listing three isolated EC50 numbers.
Pharmacology Should Be Reproducible
The ultimate goal of receptor assays is not simply to generate an attractive potency number.
It is to generate a result another laboratory could meaningfully interpret and reproduce.
That requires documenting:
- peptide identity
- concentration
- assay conditions
- receptor construct
- cell type
- incubation time
- response measurement
- reference agonist
- curve-fitting method.
The more complex the molecule, the more important those details become.
Retatrutide’s three-receptor profile makes it an especially useful example.
Conclusion
EC50 is a valuable measurement, but it represents only one part of receptor pharmacology.
Retatrutide demonstrates why.
The peptide acts as an agonist at GIPR, GLP-1R, and GCGR, yet its functional potency differs substantially across those receptors. Its strongest reported potency occurs at GIPR, while GLP-1R and GCGR require higher concentrations to reach comparable fractional responses in the reported assays.
Those numbers help characterize the molecule.
They do not tell researchers exactly how much each receptor contributes to a whole-body biological effect.
For that, receptor pharmacology has to be combined with pharmacokinetics, tissue biology, preclinical experiments, and human clinical evidence.
That is one of the central lessons of modern peptide science:
binding is not activation, potency is not efficacy, and an EC50 is not the whole mechanism.
For scientific and laboratory discussion only. Retatrutide remains an investigational compound and is not approved for human or veterinary use.
References
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022.
Wen J, et al. Next generation dual GLP-1/GIP, GLP-1/glucagon, and triple GLP-1/GIP/glucagon agonists: a literature review. 2025.
Triple Agonism Based Therapies for Obesity. 2025.
Eli Lilly and Company. What to Know About Retatrutide. Updated July 2026.